Auro Laboratories
Market Cap
₹481.5m
Last Updated
2020/10/19 12:59 UTC
Data Sources
Company Financials
Executive Summary
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet and good value.
Share Price & News
How has Auro Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 530233's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-12.0%
530233
-3.2%
IN Pharmaceuticals
-0.6%
IN Market
1 Year Return
45.5%
530233
52.6%
IN Pharmaceuticals
2.2%
IN Market
Return vs Industry: 530233 underperformed the Indian Pharmaceuticals industry which returned 53.5% over the past year.
Return vs Market: 530233 exceeded the Indian Market which returned 1.1% over the past year.
Shareholder returns
| 530233 | Industry | Market | |
|---|---|---|---|
| 7 Day | -12.0% | -3.2% | -0.6% |
| 30 Day | 35.6% | -4.3% | 0.2% |
| 90 Day | 79.7% | 13.4% | 6.7% |
| 1 Year | 45.5%45.5% | 54.5%52.6% | 3.9%2.2% |
| 3 Year | 30.4%30.4% | 26.9%23.4% | 2.6%-2.4% |
| 5 Year | 410.9%410.9% | -0.6%-4.1% | 41.3%30.8% |
Price Volatility Vs. Market
How volatile is Auro Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Auro Laboratories undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 530233 (₹77.65) is trading below our estimate of fair value (₹189.01)
Significantly Below Fair Value: 530233 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 530233 is good value based on its PE Ratio (11.2x) compared to the IN Pharmaceuticals industry average (22.9x).
PE vs Market: 530233 is good value based on its PE Ratio (11.2x) compared to the Indian market (16.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 530233's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 530233's PB Ratio (2.3x) is in line with the IN Pharmaceuticals industry average.
Next Steps
Future Growth
How is Auro Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
27.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Auro Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine whether Auro Laboratories is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Auro Laboratories competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Auro Laboratories performed over the past 5 years?
36.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 530233 has high quality earnings.
Growing Profit Margin: 530233's current net profit margins (10.3%) are higher than last year (9.7%).
Past Earnings Growth Analysis
Earnings Trend: 530233's earnings have grown significantly by 36.1% per year over the past 5 years.
Accelerating Growth: 530233's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 530233 had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).
Return on Equity
High ROE: 530233's Return on Equity (20.2%) is considered high.
Next Steps
Financial Health
How is Auro Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: 530233's short term assets (₹179.5M) exceed its short term liabilities (₹61.4M).
Long Term Liabilities: 530233's short term assets (₹179.5M) exceed its long term liabilities (₹47.2M).
Debt to Equity History and Analysis
Debt Level: 530233's debt to equity ratio (14.7%) is considered satisfactory.
Reducing Debt: 530233's debt to equity ratio has reduced from 212.8% to 14.7% over the past 5 years.
Debt Coverage: 530233's debt is well covered by operating cash flow (291.2%).
Interest Coverage: 530233's interest payments on its debt are well covered by EBIT (14.5x coverage).
Balance Sheet
Next Steps
Dividend
What is Auro Laboratories's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 530233's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 530233's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 530233's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 530233's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 530233's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
₹6m
CEO Compensation
CEO
Sharat Deorah (70 yo)
no data
Tenure
₹6,000,000
Compensation
Mr. Sharat Sahadeolal Deorah, B.Com. serves as the Managing Director and Chairman of the Board at Auro Laboratories Limited.
CEO Compensation Analysis
Compensation vs Market: Sharat's total compensation ($USD0.00) is below average for companies of similar size in the Indian market ($USD56.15K).
Compensation vs Earnings: Sharat's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Auro Laboratories Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Auro Laboratories Limited
- Ticker: 530233
- Exchange: BSE
- Founded: 1989
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹481.461m
- Shares outstanding: 6.23m
- Website: https://www.aurolabs.com
Number of Employees
Location
- Auro Laboratories Limited
- 314, T.V. Industrial Estate
- 3rd Floor
- Mumbai
- Maharashtra
- 400030
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 530233 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Oct 2004 |
Biography
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs, such as antihistamine, muscle ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/19 12:59 |
| End of Day Share Price | 2020/10/19 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.